Hepatobiliary scintigraphy and liver function changes in patients with hepatocellular carcinoma treated with 166Ho-radioembolization

Abstract Background To study the feasibility of hepatobiliary scintigraphy (HBS) to improve selection and planning of patients with hepatocellular carcinoma (HCC) treated with holmium-166 (166Ho)-microspheres radioembolization. Results Thirty-one patients with HCC were included and treated with 166H...

Full description

Saved in:
Bibliographic Details
Main Authors: Margot T.M. Reinders, Maarten J.L. Smits, Karel van Erpecum, Joep de Bruijne, Rutger C.G. Bruijnen, Dave Sprengers, Rob de Man, Erik Vegt, Jan N.M. IJzermans, Marnix G.E.H. Lam, Arthur J.A.T. Braat
Format: Article
Language:English
Published: SpringerOpen 2025-01-01
Series:EJNMMI Research
Subjects:
Online Access:https://doi.org/10.1186/s13550-025-01196-9
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1841544268340002816
author Margot T.M. Reinders
Maarten J.L. Smits
Karel van Erpecum
Joep de Bruijne
Rutger C.G. Bruijnen
Dave Sprengers
Rob de Man
Erik Vegt
Jan N.M. IJzermans
Marnix G.E.H. Lam
Arthur J.A.T. Braat
author_facet Margot T.M. Reinders
Maarten J.L. Smits
Karel van Erpecum
Joep de Bruijne
Rutger C.G. Bruijnen
Dave Sprengers
Rob de Man
Erik Vegt
Jan N.M. IJzermans
Marnix G.E.H. Lam
Arthur J.A.T. Braat
author_sort Margot T.M. Reinders
collection DOAJ
description Abstract Background To study the feasibility of hepatobiliary scintigraphy (HBS) to improve selection and planning of patients with hepatocellular carcinoma (HCC) treated with holmium-166 (166Ho)-microspheres radioembolization. Results Thirty-one patients with HCC were included and treated with 166Ho- radioembolization as part of a prospective phase 2 study. Twenty-seven patients were eligible for analysis, 67% had a cirrhotic liver morphology on imaging, 70% had multifocal disease and 51% had bilobar disease. None of the patients had clinical signs of liver decompensation (Child Pugh ≤ B7, median MELD 9 or ALBI − 2.55). Global and regional hepatic function was based on manual delineation of HBS using 200 MBq 99mTc-mebrofenine, acquired during screening and approximately three months after 166Ho-radioembolization, referred to as liver clearance rate (LCR). In line with LCR at baseline, a significant correlation was found between LCR and lab results, including bilirubin, albumin, ALT, MELD-score, and ALBI-score (p < 0.05) during follow-up. HBS showed a significant decrease in median LCR (-16%; p = 0.0017) and volume (-17%; p = 0.0027) in the treated liver, without a significant increase in the non-treated liver. Median relative change in overall LCR in non-cirrhotics was 0% (range − 23–33%), in cirrhotics − 10% (range − 40 − 19%; p = 0.40). Conclusion HBS showed that hepatic function and volume significantly decreased in parts of the liver treated with 166Ho-microspheres radioembolization in patients with HCC. Cirrhotic patients do not seem to have the capacity to increase hepatic function in the treated part of the liver. Trial registration Registry name: Clinicaltrials.gov. Trial number: NCT03379844. Date of registration: 21 November 2017. Trial URL: https://clinicaltrials.gov/study/NCT03379844?cond=hcc&term=hepar primary&rank=1#study-overview .
format Article
id doaj-art-2ddf4f51a48f469dbeaf8489d218ce28
institution Kabale University
issn 2191-219X
language English
publishDate 2025-01-01
publisher SpringerOpen
record_format Article
series EJNMMI Research
spelling doaj-art-2ddf4f51a48f469dbeaf8489d218ce282025-01-12T12:39:25ZengSpringerOpenEJNMMI Research2191-219X2025-01-0115111010.1186/s13550-025-01196-9Hepatobiliary scintigraphy and liver function changes in patients with hepatocellular carcinoma treated with 166Ho-radioembolizationMargot T.M. Reinders0Maarten J.L. Smits1Karel van Erpecum2Joep de Bruijne3Rutger C.G. Bruijnen4Dave Sprengers5Rob de Man6Erik Vegt7Jan N.M. IJzermans8Marnix G.E.H. Lam9Arthur J.A.T. Braat10Department of Radiology & Nuclear Medicine, University Medical Center UtrechtDepartment of Radiology & Nuclear Medicine, University Medical Center UtrechtDepartment of Gastroenterology & Hepatology, Utrecht University - University Medical Center UtrechtDepartment of Gastroenterology & Hepatology, Utrecht University - University Medical Center UtrechtDepartment of Radiology & Nuclear Medicine, University Medical Center UtrechtDepartment of Gastroenterology & Hepatology, Erasmus MC-University Medical CentreDepartment of Gastroenterology & Hepatology, Erasmus MC-University Medical CentreDepartment of Radiology & Nuclear Medicine, Erasmus MC-University Medical CentreDepartment of Surgery, Erasmus MC-University Medical CentreDepartment of Radiology & Nuclear Medicine, University Medical Center UtrechtDepartment of Radiology & Nuclear Medicine, University Medical Center UtrechtAbstract Background To study the feasibility of hepatobiliary scintigraphy (HBS) to improve selection and planning of patients with hepatocellular carcinoma (HCC) treated with holmium-166 (166Ho)-microspheres radioembolization. Results Thirty-one patients with HCC were included and treated with 166Ho- radioembolization as part of a prospective phase 2 study. Twenty-seven patients were eligible for analysis, 67% had a cirrhotic liver morphology on imaging, 70% had multifocal disease and 51% had bilobar disease. None of the patients had clinical signs of liver decompensation (Child Pugh ≤ B7, median MELD 9 or ALBI − 2.55). Global and regional hepatic function was based on manual delineation of HBS using 200 MBq 99mTc-mebrofenine, acquired during screening and approximately three months after 166Ho-radioembolization, referred to as liver clearance rate (LCR). In line with LCR at baseline, a significant correlation was found between LCR and lab results, including bilirubin, albumin, ALT, MELD-score, and ALBI-score (p < 0.05) during follow-up. HBS showed a significant decrease in median LCR (-16%; p = 0.0017) and volume (-17%; p = 0.0027) in the treated liver, without a significant increase in the non-treated liver. Median relative change in overall LCR in non-cirrhotics was 0% (range − 23–33%), in cirrhotics − 10% (range − 40 − 19%; p = 0.40). Conclusion HBS showed that hepatic function and volume significantly decreased in parts of the liver treated with 166Ho-microspheres radioembolization in patients with HCC. Cirrhotic patients do not seem to have the capacity to increase hepatic function in the treated part of the liver. Trial registration Registry name: Clinicaltrials.gov. Trial number: NCT03379844. Date of registration: 21 November 2017. Trial URL: https://clinicaltrials.gov/study/NCT03379844?cond=hcc&term=hepar primary&rank=1#study-overview .https://doi.org/10.1186/s13550-025-01196-9Hepatobiliary scintigraphyHolmiumRadioembolizationHepatocellular carcinomaHepatic functionLiver clearance rate
spellingShingle Margot T.M. Reinders
Maarten J.L. Smits
Karel van Erpecum
Joep de Bruijne
Rutger C.G. Bruijnen
Dave Sprengers
Rob de Man
Erik Vegt
Jan N.M. IJzermans
Marnix G.E.H. Lam
Arthur J.A.T. Braat
Hepatobiliary scintigraphy and liver function changes in patients with hepatocellular carcinoma treated with 166Ho-radioembolization
EJNMMI Research
Hepatobiliary scintigraphy
Holmium
Radioembolization
Hepatocellular carcinoma
Hepatic function
Liver clearance rate
title Hepatobiliary scintigraphy and liver function changes in patients with hepatocellular carcinoma treated with 166Ho-radioembolization
title_full Hepatobiliary scintigraphy and liver function changes in patients with hepatocellular carcinoma treated with 166Ho-radioembolization
title_fullStr Hepatobiliary scintigraphy and liver function changes in patients with hepatocellular carcinoma treated with 166Ho-radioembolization
title_full_unstemmed Hepatobiliary scintigraphy and liver function changes in patients with hepatocellular carcinoma treated with 166Ho-radioembolization
title_short Hepatobiliary scintigraphy and liver function changes in patients with hepatocellular carcinoma treated with 166Ho-radioembolization
title_sort hepatobiliary scintigraphy and liver function changes in patients with hepatocellular carcinoma treated with 166ho radioembolization
topic Hepatobiliary scintigraphy
Holmium
Radioembolization
Hepatocellular carcinoma
Hepatic function
Liver clearance rate
url https://doi.org/10.1186/s13550-025-01196-9
work_keys_str_mv AT margottmreinders hepatobiliaryscintigraphyandliverfunctionchangesinpatientswithhepatocellularcarcinomatreatedwith166horadioembolization
AT maartenjlsmits hepatobiliaryscintigraphyandliverfunctionchangesinpatientswithhepatocellularcarcinomatreatedwith166horadioembolization
AT karelvanerpecum hepatobiliaryscintigraphyandliverfunctionchangesinpatientswithhepatocellularcarcinomatreatedwith166horadioembolization
AT joepdebruijne hepatobiliaryscintigraphyandliverfunctionchangesinpatientswithhepatocellularcarcinomatreatedwith166horadioembolization
AT rutgercgbruijnen hepatobiliaryscintigraphyandliverfunctionchangesinpatientswithhepatocellularcarcinomatreatedwith166horadioembolization
AT davesprengers hepatobiliaryscintigraphyandliverfunctionchangesinpatientswithhepatocellularcarcinomatreatedwith166horadioembolization
AT robdeman hepatobiliaryscintigraphyandliverfunctionchangesinpatientswithhepatocellularcarcinomatreatedwith166horadioembolization
AT erikvegt hepatobiliaryscintigraphyandliverfunctionchangesinpatientswithhepatocellularcarcinomatreatedwith166horadioembolization
AT jannmijzermans hepatobiliaryscintigraphyandliverfunctionchangesinpatientswithhepatocellularcarcinomatreatedwith166horadioembolization
AT marnixgehlam hepatobiliaryscintigraphyandliverfunctionchangesinpatientswithhepatocellularcarcinomatreatedwith166horadioembolization
AT arthurjatbraat hepatobiliaryscintigraphyandliverfunctionchangesinpatientswithhepatocellularcarcinomatreatedwith166horadioembolization